

- infection, *Ann Surg* 226, 450-458; discussion 458-460 (1997). [45] Regan, M. C., *Host defense dysfunction in trauma, shock and sepsis: mechanisms and therapeutic approaches*, (Springer, Berlin, 1993). [46] Robson, M. C., Wound infection. A failure of wound healing caused by an imbalance of bacteria, *Surg Clin North Am* 77, 637-650 (1997). [47] Medzhitov, R., Recognition of microorganisms and activation of the immune response, *Nature* 449, 819-826 (2007). [48] Dinarello, C. A., Proinflammatory cytokines, *Chest* 118:503-508 (2000). [49] Foex, B. A., et al., Early cytokine response to multiple injury, *Injury* 24:373-376 (1993). [50] Jemal A, Siegel R, Ward E, et al., *Cancer Statistics 2009*, *CA Cancer J Clin* 2009 July-August; 59(4):225-49. [51] *Cancer Facts and Figures 2008*, Atlanta, Ga.; American Cancer Society: 2009. [52] *Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis*, Joy J E, Penhoet E E, and Petitti D B, eds., Institute of Medicine and National Research Council of the National Academies, National Academy Press, Washington D.C., 2004. [53] Winchester D P, Osteen R T, Menck H R, *The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age*, *Cancer* 1996; 78:1838-1843. [54] Chung M, Chang H R, Bland K I, Wanebo H J, Younger women with breast carcinoma have a poorer prognosis than older women, *Cancer* 1996; 77:97-103. [55] Xiong Q, Valero V, Kau V, et al., Female patients with breast carcinoma age 30 years and younger have a poor prognosis: The M. D. Anderson Cancer Center experience, *Cancer* 2001; 92(10): 2523-8. [56] Smith R A, Saslow D, Sawyer K A, et al., *American Cancer Society guidelines for breast cancer screening: update 2003*, *CA Cancer J Clin* 2003; 53(3): 141-69. [57] Kollias J, Sibbering D M, Blamey R W, et al., Screening women aged less than 50 years with a family history of breast cancer, *Eur J Cancer* 1998; 34:878-83. [58] Tilanus-Lindhorst M M, Bartels C C, Obedijn A L, Oudkerk M., Earlier detection of breast cancer by surveillance of women at familial risk, *Eur J Cancer* 2000; 36:514-19. [59] Carney P A, Miglioretti D L, Yankaskas B C, et al., Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography, *Ann. Intern. Med* 2003; 138(3): 168-175. [60] Kroenke C H, Rosner B, Chen W Y, Kawachi I, Colditz G A, Holmes M D, Functional impact of breast cancer by age at diagnosis, *J Clin Oncol* 2004; 22(10): 1849-56. [61] Warner E, Plewes D B, Hill K A, et al., Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast exam, *JAMA* 2004; 292:1317-1325. [62] Morris E A, Schwartz L H, Dershaw D D, et al., MR imaging of the breast in patients with occult primary breast carcinoma, *Radiology* 1997; 205:437-440. [63] Orel S G, Schnall M D, LiVolsi V A, et al., Suspicious breast lesions: MR imaging with radiologic-pathologic correlation, *Radiology* 1994; 190:485-493. [64] Visvanathan K, Chlebowski R T, Hurley P, et al., American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction, *J Clin Oncol*. 2009 Jul. 1; 27(19):3235-58. Epub 2009 May 26. [65] Fisher B, Costantino J P, Wickerham D L, et al., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, *JNCI* 1998; 90 (18): 1371-88. [66] Grann V R, Sundararajan V, Jacobson J S, et al., Decision analysis of tamoxifen for the prevention of invasive breast cancer, *Cancer J Sci Am* 2000; 6:169-178. [67] Hershman D, Sundararajan V, Jacobson J S, et al., Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis, *J Clin Oncol* 2001; 20:9-16. [68] MacKarem G., The effectiveness of the Gail model in estimating risk for development of breast cancer in women under 40 years of age, *Breast Journal* 2001; 7(1):34-9. [69] Stojadinovic A, Nissan A, Gallimidi Z, et al., Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women Preliminary Results of a Multi-Center Prospective Trial, *Journal of Clinical Oncology* 2005 Apr. 20; 23(12):2703-15. [70] Livak, K. J., and Schmittgen, T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta Delta C(T)} Method. *Methods* 25: 402-408, 2001.
1. A method for determining a patient-specific probability of impaired wound healing, said method including:
 - collecting clinical parameters from a plurality of patients to create a training database, the clinical parameters including biomarker levels from at least one of serum, wound effluent and biopsy tissue, the biomarker levels including gene expression levels for an IP-10 gene, IL-6 gene, MCP-1 gene, IL-5 gene, and RANTES gene;
 - creating a fully unsupervised Bayesian Belief Network model using data from the training database;
 - validating the fully unsupervised Bayesian Belief Network model;
 - collecting the clinical parameters for an individual patient;
 - receiving the clinical parameters for the individual patient into the fully unsupervised Bayesian Belief Network model;
 - outputting the patient-specific probability of impaired wound healing from the fully unsupervised Bayesian Belief Network model to a graphical user interface for use by a clinician; and
 - updating the fully unsupervised Bayesian Belief Network model using the clinical parameters for the individual patient and the patient-specific probability of impaired wound healing.
 2. The method according to claim 1, wherein the biomarker levels include:
 - a first gene expression level for the IP-10 gene taken from the serum on a first measurement day;
 - a second gene expression level for the IP-10 gene taken from the serum on a second measurement day;
 - a third gene expression level for the IP-10 gene taken from the serum on a third measurement day;
 - a fourth gene expression level for the IL-6 taken from the serum on the first measurement day;
 - a fifth gene expression level for the IL-6 taken from the serum on the third measurement day;
 - a sixth gene expression level for the MCP-1 gene taken from the wound effluent on the first measurement day;
 - a seventh gene expression level for the MCP-1 gene taken from the serum on the first measurement day;
 - a eighth gene expression level for the MCP-1 gene taken from the serum on the second measurement day;
 - a ninth gene expression level for the MCP-1 gene taken from the serum on a thirtieth measurement day;
 - a tenth gene expression level for the IL-5 gene taken from the wound effluent on the third measurement day;